Pharmacokinetics and Pharmacodynamics of Antifungals

Infectious Disease Clinics of North America

Volumn 20, Issue 3, 2006, Pages 679-697

  Andes, David ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCANDIN; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CILOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TOXICITY; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; DISEASE MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG USE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW;

ANTIFUNGAL AGENTS; HUMANS; MYCOSES;

EID: 33748557483     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.06.007     Document Type: Review

References (89)

1. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-12
2. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47 (2003) 1179-1186
3. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2 (2004) 289-300
4. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeast; approved standard. Document M27-A (1997), National Committee for Clinical Laboratory Standards, Wayne, PA
5. Pfaller M.A., Diekema D.J., Rex J.H., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 44 (2006) 819-826
6. Rex J.H., Pfaller M.A., Galgiani J.N., et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro and in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 24 (1997) 235-247
7. Smith J., and Andes D. Pharmacokinetics of antifungal drugs; implications for drug selection. Infect Med 23 (2006) 328-333
8. Groll A.H., Giri N., Petraitis V., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 182 (2000) 274-282
9. Gauthier G.M., Nork T.M., Prince R., et al. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41 (2005) 27-28
10. Savani D.V., Perfect J.R., Cobo L.M., et al. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 31 (1987) 6-10
11. Fisher J.F., Taylor A.T., Clark J., et al. Penetration of amphotericin B into the human eye. J Infect Dis 147 (1983) 164
12. Sorensen K.N., Sobel R.A., Clemons K.V., et al. Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. Antimicrob Agents Chemother 44 (2000) 1512-1517
13. Perfect J.R., Savani D.V., and Durack D.T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother 29 (1986) 579-583
14. Purkins L., Wood N., Ghahramani P., et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46 (2002) 2546-2553
15. Brammer K.W., Farrow P.R., and Faulkner J.K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12 Suppl 3 (1990) S318-S326
16. Craig WA, Suh B. Protein binding and the antimicrobial effects: methods for the determination of protein binding. In Lorian V, editor. Antibiotics in laboratory medicine. 4th editor. Williams & Wilkins Co.; Baltimore, MD; 1996. p. 367-402.
17. Dudley M.N., and Ambrose P.G. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr Opin Microbiol 3 (2000) 515-521
18. Ernst E.J., Klepser M.E., and Pfaller M.A. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 44 (2000) 1108-1111
19. Klepser M.E., Malone D., Lewis R.E., et al. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 44 (2000) 1917-1920
20. Ernst E.J., Klepser M.E., and Pfaller M.A. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 44 (2000) 1008-1011
21. Turnidge J.D., Gudmundsson S., Vogelman B., et al. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 34 (1994) 83-92
22. Andes D., and Van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43 (1999) 2116-2120
23. Andes D., Marchillo K., Stamstad T., et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47 (2003) 3165-3169
24. Andes D., Marchillo K., Conklin R., et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 48 (2004) 137-142
25. Andes D., Marchillo K., Stamstad T., et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47 (2003) 1193-1199
26. Lewis R.E., Wiederhold N.P., and Klepser M.E. In vitro pharmacodynamics of amphotericin b, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 49 (2005) 945-951
27. Louie A., Drusano G.L., Banerjee P., et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 42 (1998) 1105-1109
28. Andes D., Forrest A., Lepak A., et al. Antimicrobial dosing regimen impact on the evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother 50 (2006) 2374-2383
29. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
30. Stevens D.A., Kan L.V., Judson M.A., et al. practice guidelines for diseases caused by aspergillus. Clin Infect Dis 30 (2000) 696-709
31. Baily G.G., Perry F.M., Denning D.W., et al. Fluconazole resistant candidiasis in an HIV cohort. AIDS 8 (1994) 787-792
32. Barchiesi F., Hollis R.J., McGough D.A., et al. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis 20 (1995) 634-640
33. Bart-Delabesse E., Boiron P., Carlotti A., et al. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 31 (1993) 2933-2937
34. Boken D.J., Swindells S., and Rinaldi M.G. Fluconazole-resistant Candida albicans. Clin Infect Dis 17 (1993) 1018-1021
35. He X., Tiballi R.N., Zarins L.T., et al. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 38 (1994) 2495-2497
36. Heinic G.S., Stevens D.A., Greenspan D., et al. Fluconazole-resistant Candida in AIDS patients: report of two cases. Oral Surg Oral Med Oral Pathol 76 (1993) 711-715
37. Newman S.L., Flanigan T.P., Fisher A., et al. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 19 (1994) 684-686
38. Pfaller M.A., Rhine-Chalberg J., Redding S.W., et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 32 (1994) 59-64
39. Redding S., Smith J., Farinacci G., et al. Resistance to Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in patients with AIDS: documentation of in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 18 (1994) 240-242
40. Reynes J., Mallie M., Andre D., et al. Traitement et prophylxie secondarire par fluconazole des candidoses oropharyngees des suets VIH +. Analyse mycologique des echecs. Pathol Biol 40 (1992) 513-517
41. Rodriguez-Tudela JL, Laguna F, Martinez-Suarez JV, et al. Fluconazole resistance of Candida albicans isolates from AIDS patients receiving prolonged antifungal therapy [abstract 1204]. Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans (LA), October 17-20, 1992.
42. Ruhnke M., Eigler A., Engelmann E., et al. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22 (1994) 132-136
43. Ruhnke M., Eigler A., Tennagen I., et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 32 (1994) 2092-2098
44. Sandven P., Bjorneklett A., and Maeland A. Norwegian Yeast Study Group. Susceptibility testing of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chemother 37 (1993) 2443-2448
45. Sangeorzan J.A., Bradley S.F., He X., et al. Epidemiology of oral candidiasis in HIV infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 97 (1994) 339-346
46. Ghannoum M.A., Rex J.H., and Galgiani J.N. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 34 (1996) 489-495
47. Cartledge J.D., Midgley J., Petrou M., et al. Unresponsive HIV-related oro-oesophageal candidosis: an evaluation of two new in vitro azole susceptibility tests. J Antimicrob Chemother 40 (1997) 517-523
48. Dannaoui E., Colin S., Pichot J., et al. Evaluation of the ETEST for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis. Eur J Clin Microbiol Infect Dis 16 (1997) 228-232
49. Revankar S.G., Dib O.P., Kirkpatrick W.R., et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 26 (1998) 960-963
50. Quereda C., Polanco A.M., Giner C., et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 15 (1996) 30-37
51. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 17 331 (1994) 1325-1330
52. Takakura S., Fujihara N., Saito T., et al. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 23 (2004) 380-388
53. Lee S.C., Fung C.P., Huang J.S., et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 44 (2000) 2715-2718
54. Clancy C.J., Yu V.L., Morris A.J., et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 49 (2005) 3171-3177
55. Alexander B., Schell W.A., Miller J.L., et al. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 27 (2005) 868-871
56. Imhof A., Balajee S.A., Fredricks D.N., et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39 (2004) 743-746
57. Marty F.M., Cosimi L.A., and Baden L. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350 (2004) 950-952
58. Siwek G.T., Dodgson K.J., de Magalhaes-Silvermanet M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 39 (2004) 584-587
59. Smith J., Safdar N., Knasinski V., et al. Consideration of voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50 (2006) 1570-1572
60. Gunderson S.M., Hoffman H., Ernst E.J., et al. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect. Antimicrob Agents Chemother 44 (2000) 2887-2890
61. Andes D., Stamstad T., and Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 45 (2001) 922-926
62. Andes D., Safdar N., Marchillo K., et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 50 (2006) 674-684
63. Wiederhold N.P., Tam V.H., Chi J., et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50 (2006) 469-473
64. Park B.J., Arthington-Skaggs B.A., Hajjeh R.A., et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 50 (2006) 1287-1292
65. Hong Y., Shaw P.J., Nath C.E., et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 50 (2006) 935-942
66. Andes D., and Van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 44 (2000) 938-942
67. Hope W.W., Warn P.A., Sharp A., et al. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. J Infect Dis 192 (2005) 673-680
68. Te Dorsthorst D.T.A., Verweij P.E., Meis J.F.G.M., et al. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Chemother 48 (2004) 2007-2013
69. Te Dorsthorst D.T.A., Verweij P.E., Meis G.F.J.M., et al. Efficacy and Pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. Antimicrob Agents Chemother 49 (2005) 4220-4226
70. Karyotakis N.C., and Anaissie E.J. Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis. Antimicrob Agents Chemother 40 (1996) 2907-2908
71. Francis P., and Walsh T.J. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 15 (1992) 1003-1018
72. Polak A., Eschenhof E., Fernex M., et al. Metabolic studies with 5-fluorocytosine-6-14C in mouse, rat, rabbit, dog and man. Chemotherapy 22 (1976) 137-153
73. Ernst E.J., Roling E.E., Petzold C.R., et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 46 (2002) 3846-3853
74. Andes D., Marchillo K., Lowther J., et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 47 (2003) 1187-1192
75. Walsh T.J., Lee J.W., Kelly P., et al. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1, 3-3-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother 35 (1991) 1321-1328
76. Louie A., Deziel M., Liu W., et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 49 (2005) 5058-5068
77. Wiederhold N.P., Kontoyiannis D.P., Chi J., et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 190 (2004) 1464-1471
78. Pfaller M.A., Diekema D.J., Boyken L., et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 49 (2005) 4795-4797
79. de Wet N., Llanos-Cuentas A., Suleiman J., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39 (2004) 842-849
80. Krause D.S., Reinhardt J., Vazquez J.A., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 48 (2004) 2021-2024
81. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24 (2005) 654-661
82. Buell D., Kovanda L., Drake T., et al. Alternate day dosing of micafungin in treatment of esophageal candidiasis. ICAAC M719 (2006) 419
83. Bennett J.E., Dismukes W.E., Duma R.J., et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301 (1979) 126-131
84. MacCallum D.M., Whyte J.A., and Odds F.C. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 49 (2005) 3697-3701
85. Kirkpatrick W.R., Perea S., Coco B.J., et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 46 (2002) 2564-2568
86. Warn P.A., Sharp A., Morrissey G., et al. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. J Antimicrob Chemother 56 (2005) 590-593
87. Mouton J.W., Van Ogtrop J.W., Andes D., et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 43 (1999) 2473-2478
88. Meletiadis J., Verweij P.E., te Dorsthorst D.T.A., et al. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol 43 (2005) 133-152
89. Lewis R.E., and Kontoyiannis D.P. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob Chemother 56 (2005) 887-892